Thus, to provide a comprehensive evaluation of the basis of FGF21 abnormalities in metabolic disease, we analyzed the association between rs838133 and the expression of molecular actors of FGF21 responsiveness (FGFRs and KLB) in liver and adipose tissue. Here, KLB is linked to Other metabolic disease.